Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?

Jung, Jin Woo; Yu, Young Dong; Lee, Young Ju; Kim, Jung Jun; Lee, Hak Min; Oh, Jong Jin; Lee, Sangchul; Lee, Sang Wook; Lee, Sang Eun; Jeong, Seong Jin

doi:10.4103/aja.aja_66_18

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in our study, we found that the improvement in TPV prediction using PSA mass compared to serum PSA was minimal. These results are consistent with previous studies reporting only modest improvements in TPV prediction with the use of PSA mass [21]. It is possible that the effect of PSA mass on TPV estimation may differ between regions, and further studies are needed to explore this potential variability.…”

Section: Discussionsupporting

confidence: 91%

A novel nomogram using PSA mass for predicting BPH

2023

JOMH

View full text Add to dashboard Cite

In 2019, there were 94 million cases of benign prostatic hyperplasia globally among men aged 40 years and older. Assessment of prostate volume (PV) is important in evaluating lower urinary tract symptoms and risks in asymptomatic individuals. Serum prostatespecific antigen (PSA) levels have been suggested as a convenient and useful biomarker for benign prostate hyperplasia (BPH). However, studies suggest that using PSA as a biomarker for BPH and prostate cancer can lead to underestimation of disease severity in patients with a high body mass index (BMI). PSA mass has been proposed as a potentially superior predictor compared to total PSA levels. This retrospective study recruited the male patients visiting Kuang Tien General Hospital who had serum PSA level test, underwent transrectal ultrasonography (TRUS) for evaluation of prostate volume between January 2009 and December 2019. PSA mass was obtained by calculating body surface area (BSA) and plasma volume. The data were proved to build a nomogram, to predict the volume of the prostate, and its accuracy was evaluated using internal validation techniques. Statistical analyses were performed using SAS and R. A total of 417 men were included in this study, with a mean age of 67.3 years, mean BMI of 24.9 kg/m 2 , mean prostate volume of 43.87 mL, mean PSA level of 2.94 ng/mL, and mean PSA mass of 8.68 ng/mL. The results showed that PSA mass had a higher accuracy than PSA in predicting prostate volume, as evidenced by a higher area under curve (AUC) value of 0.8271 for the PSA mass model compared to 0.8218 for the PSA model. Our nomogram showed a satisfying prediction accuracy. PSA mass may be a superior predictor of prostate volume compared to total PSA levels, although only slight improvement was shown.

show abstract

Section: Discussionsupporting

confidence: 91%

A novel nomogram using PSA mass for predicting BPH

2023

JOMH

View full text Add to dashboard Cite

show abstract

Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients

et al. 2019

View full text Add to dashboard Cite

Aims Several studies have reported a potential association between prostate volume (PV) and prostate disease. Here, we classified the risk factors for PV among benign prostatic hyperplasia (BPH) patients. Methods In all, 4293 BPH patients with available clinical information were enrolled. Body mass index (BMI) was obtained as weight divided by height squared. PV was calculated as length × width × height (cm) × π/6. Mann‐Whitney U tests were used to determine the differences between PV subgroups. Univariate and multiple linear regression tests were performed to uncover the connection between clinical features and PV. The differences in the age, BMI, height and fasting blood glucose (FBG) of the subgroups were evaluated by Kruskal‐Wallis tests and adjusted with Bonferroni post hoc correction. A nomogram was created to directly illustrate the mutual interaction of amalgamator parameters. Results PV did not influence the incidence of kidney stones (P = .815), whereas prostate calculi were positively associated with an enlarged prostate (>30 mL) (P < .001). Age (adjusted R = 0.363, P < .001), height (adjusted R = 0.088, P < .001), BMI (adjusted R = 0.039, P = .013) and FBG (adjusted R = −0.034, P = .027) were the independent risk/protective factors related to enlarged PV among BPH patients. The nomogram illustrated the predictive risk of an enlarged prostate (>30 mL) in men. The area under the ROC curve value was 0.659 in the training cohort and 0.677 in an internal validation cohort. Conclusions Age, height and BMI were positive independent risk factors of enlarged PV in BPH patients, and FBG had a protective role.

show abstract

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?

Cited by 2 publications

References 30 publications

A novel nomogram using PSA mass for predicting BPH

A novel nomogram using PSA mass for predicting BPH

Age, height, BMI and FBG predict prostate volume in ageing benign prostatic hyperplasia: Evidence from 5285 patients

Contact Info

Product

Resources

About